Objective: Visceral adipose tissue (VAT) is associated with an increased risk of metabolic syndrome (MetS). Recent studies have suggested that VAT negatively affects bone. However, MetS has also been associated with higher estradiol (E 2 ) levels, which is bone protective. We therefore investigated the impact of VAT and E 2 levels on bone density, structural parameters, and strength estimates. Design: A cross-sectional study was conducted in 72 obese men with MetS to investigate the impact of VAT and E 2 levels on bone. Methods: Bone parameters were assessed by dual-energy X-ray absorptiometry (DXA), quantitative computed tomography (QCT), and high-resolution peripheral QCT (HRpQCT) at lumbar spine, proximal femur, radius, and tibia. VAT volume was measured by magnetic resonance imaging (MRI) and sexual hormones were measured in blood samples. Results: Men with high VAT had a lower bone density at the hip (P!0.05), lower cortical thickness, and higher buckling ratio at femoral neck (FN) (PZ0.008 and PZ0.02), compared with men with low VAT, despite a similar body weight and BMI. Generally, E 2 levels were low (median 43 pmol/l), and men with E 2 levels below median had reduced bone density at lumbar spine (PZ0.04), and impaired structural parameters at radius and tibia, compared with men with E 2 levels above median. At the hip, VAT volume and E 2 levels affected bone density independently and additively, and 50% of men with high VAT and low E 2 levels had osteopenia with significantly lower T-score at FN (PZ0.004). Conclusions: High VAT and low E 2 negatively affect bone in obese men with MetS. VAT and E 2 affect bone density at the hip independently and additively, revealing an unexpected high prevalence of osteopenia in middle-aged men with MetS.
Introduction
The prevalence of obesity and osteoporosis has rapidly increased over the last decades (1, 2) . The bone-fat relationship has proven to be complex and published results in the field have been ambiguous. Body weight and BMI are positively correlated with bone mineral density (BMD) (3, 4, 5). However, obese individuals seem to have increased fracture risk regardless of a higher BMD (6, 7, 8) , and similarly for patients with type 2 diabetes (9, 10, 11). Obesity, metabolic syndrome (MetS), and type 2 diabetes are all associated with low-grade inflammation (12, 13) . As visceral adipose tissue (VAT) produces inflammatory cytokines that are harmful to bone, research has focusedincreased aromatase activity and increased levels of estradiol (E 2 ) (18, 19) , which is bone protective (20) . Khosla et al. (21) found no association between bone density and sex steroid levels in eugonadal young men, but did find positive associations between bone density and low testosterone and E 2 levels in elderly men.
The effect of VAT on bone has previously been investigated in a number of studies. Gilsanz et al. (22) showed that, in young women, VAT was negatively correlated with BMD, whereas subcutaneous adipose tissue (SAT) was positively correlated with BMD. Yamaguchi et al. (23) showed that, in men with type 2 diabetes, both SAT and VAT were positively correlated with BMD. When data were adjusted for body weight, opposing results emerged, but VAT remained inversely related to the risk of vertebral fractures. Finally, Choi et al. (24) found that VAT was negatively correlated with BMD, whereas SAT was positively correlated with BMD in Korean men and women, after adjusting for body weight. These seemingly conflicting results may be due to the fact that SAT, VAT, waist circumference (WC), and BMI are highly correlated in most populations (25, 26) and this may potentially disturb statistical analyses due to collinearity.
We therefore investigated the impact of visceral fat volume and serum levels of E 2 on areal BMD (aBMD), volumetric BMD (vBMD), bone structure, and estimates of bone strength in a very homogeneous population of obese middle-aged men with MetS.
Subjects and methods

Study design and subjects
This was a cross-sectional study on baseline data from a randomized, placebo-controlled, double-blinded, singlecenter study (27) . Seventy-two subjects were included in this study. Inclusion criteria were male sex, age between 30 and 60 years, and MetS. MetS was defined according to the International Diabetes Federation (28) as central obesity (WC R94 cm and/or BMI O30 kg/m 2 ) plus any two of the following: raised triglycerides (R1.7 mmol/l), reduced HDL (%1.03 mmol/l), raised blood pressure (systolic R130 mmHg or diastolic R85 mmHg), raised fasting plasma glucose (R5.6 mmol/l), or drug treatment for the individual features. Exclusion criteria were other overt endocrine diseases, renal disease, hepatic disease, heart disease, malignant disease, anemia, alcohol abuse, planned lifestyle changes, and absolute or relative contraindications for magnetic resonance imaging (MRI).
Ethical aspects
The protocol was approved by the Regional Committee on Health Research Ethics (M-20110111) and the Danish Data Protection Agency, and the study was conducted in agreement with the Declaration of Helsinki II. Participants were given oral and written information about the purpose and nature of all procedures before informed consent was obtained. The protocol was registered at clinicaltrials.gov (NCT01412645) before recruitment was initiated.
Magnetic resonance imaging
VAT and SAT were determined with MRI using a fast spin echo sequence (Signa Excite 1.5 Tesla, Twin Speed; GE Medical Systems, Little Chalfont, Bucks, UK). Axial slices were obtained from the proximal border of the femoral heads to the upper pole of the most superior kidney, and Hippo Fat was used for data processing, providing estimates for SAT and VAT (29, 30) .
Dual-energy X-ray absorptiometry
aBMD at the lumbar spine (L1-L4) and hip was measured by dual-energy X-ray absorptiometry (DXA) using a Hologic Discovery scanner. Coefficient of variation (CV) of repositioning is 1.5% for lumbar spine BMD and 2.1% for femoral neck (FN) (31, 32) . In addition, whole-body fat mass and lean body mass were measured by DXA.
Quantitative computed tomography
vBMD at lumbar vertebra 2 (LS vBMD) and the proximal femur was measured using a Philips Brilliance 40 multidetector helical CT scanner. CT scans were acquired from the distal endplate of L1 to the proximal endplate of L3, and from acetabulum directly above the femoral head to 2 cm below the lesser trochanter (TR), with 3 mm slice thickness and spacing as described previously (27) . M J Ornstrup analyzed all quantitative computed tomography (QCT) data, blinded to VAT distribution and E 2 levels, with a reanalysis precision of 0.6G0.6% for lumbar spine (LS) vBMD trab , and 0.6G0.7% for total hip (TH) vBMD integral . We determined vBMD integral in standard regions (TH, FN, TR, and intertrochanteric (IT)), along with separate trabecular estimates (vBMD trab ) and cortical estimates (vBMD cortical ). A fixed threshold for cortical separation of 0.350 g/cm 3 was used. Geometric measures at the FN; cross-sectional area (CSA) total , CSA cortical , and cortical thickness (Ct.Th), along with estimates of bone strength (cross-sectional moment of inertia (CSMI) and buckling ratio) were determined (33, 34, 35) .
High-resolution peripheral QCT
Assessment of geometry and microarchitecture of the non-dominant distal radius and tibia (or in case of a previous fracture in the non-fractured limb) were obtained using high-resolution peripheral QCT (HRpQCT) (XtremeCT, Scanco Medical, Brüttisellen, Switzerland) as described previously (27) . The analysis was performed by M J Ornstrup, who was blinded to VAT distribution and E 2 levels. CV of repositioning for radius and tibia density measures were 0.5-1.5% and the structural parameters 1-5% (36, 37 
Biochemistry
We analyzed bone alkaline phosphatase (BAP), osteoprotegerin (OPG), osteocalcin (intact and N-terminal fragment), and procollagen 1 N-terminal propeptide (P1NP) as markers of bone formation. As markers of bone resorption, we analyzed C-terminal telopeptide of type 1 collagen (CTx), and cross-linked N-terminal telopeptide of type 1 collagen (NTx). In addition, parathyroid hormone (PTH) and 25-hydroxy vitamin D were measured. All analyses were performed by standard laboratory methods at the Department of Clinical Biochemistry (Aarhus University Hospital, Denmark), except OPG. OPG was measured using ELISA OPG Kit (Biomedica, Vienna, Austria). Intra-and inter-assay CV values were 4 and 5% respectively. Markers reflecting metabolic state were measured; triglyceride, HDL, and alanine transaminase (ALT) were performed by standard laboratory methods at the Department of Clinical Biochemistry (Aarhus University Hospital, Denmark). Interleukin 6 (IL6), high-sensitivity C-reactive protein (hs-CRP), leptin, and adiponectin were analyzed using ELISA as described previously (39) , and glucose using ELISA Kit from Roche with intra-and interassay CV values of 3 and 4% respectively. Sex steroid hormones (E 2 , estrone, testosterone, androstenedione, and sex hormone-binding globulin (SHBG)) were measured by standard laboratory methods at the Danish National Health Laboratory.
Statistical analysis
Normality was checked by QQ-plots, and test for equal variance between groups was assessed by Levene's test for equal variances. The level of significance was 0.05. Analyses and graphs were performed with IBM SPSS Statistics (version 20), and SigmaPlot (version 12.5). Correlations between two variables were assessed by the Spearman's rank-order correlation. To determine the effect of VAT and E 2 on vBMD, structural bone parameters, and strength estimates, the study subjects were divided into two groups based on VAT median and E 2 median. Men with VAT below the median were grouped in VAT low , and men with VAT above the median were grouped in VAT high . Additionally, study subjects were divided into E 2 low and E 2 high according to E 2 levels below and above E 2 median.
To adjust for multiple comparisons, the multivariate t-test (Hotelling's t-test) was performed on biochemical markers of bone turnover and QCT-derived hip parameters. Variable dependency is accounted for within this multivariate test. Thereafter, differences between VAT groups and E 2 groups, respectively, were assessed by unpaired Student's t-test, or the Mann-Whitney rank sum test. Results are presented as meanGS.D. or as median with interquartile (25%; 75%) range. Multiple linear regression analysis was used to investigate whether VAT group and E 2 group had independent impact on bone density at the hip. Finally, the population was divided according to VAT volume and E 2 levels into four groups (E 2 low CVAT high , E 2 low CVAT low , E 2 high CVAT high , and E 2 high CVAT low ), and ANOVA with Student-Newman-Keuls post hoc adjustment was used to assess differences between groups. 
Results
Population characteristics
Clinical and metabolic characteristics across visceral fat mass median
Median VAT for VAT low and VAT high groups were 2239 and 3283 cm 3 respectively (P!0.001). Clinical characteristics such as age, weight, BMI, and WC did not differ between groups (Table 1 ). Other measures of fat distribution, including whole-body fat mass (by DXA), and subcutaneous fat mass (MRI) did not differ between groups either (Table 1 ). The level of ALT was significantly higher in the VAT high group, IL6 borderline was significantly higher, and HDL was significantly lower in the VAT high group (Table 1) . Other metabolic markers, including insulin, adiponectin, and leptin, were not different between groups (Table 1) .
Bone density and structural parameters across visceral fat median vBMD integral at TH was significantly lower in the VAT high group compared with the VAT low group (PZ0.01). Similar results were found at FN, TR, and IT, although only borderline significant at TR ( Table 2 ). In addition, the subanalysis of vBMD trab at TH was significantly lower in the VAT high group (PZ0.02), with similar site-specific effects at FN, TR, and IT (Table 2) . vBMD cortical at TH was higher in the VAT high group compared with the VAT low group (PZ0.01), and similarly at IT. At FN and TR, vBMD cortical did not differ between groups (Table 2) . CSA total at FN was similar across VAT groups (Table 2) , while FN CSA cortical and Ct.Th were significantly lower in the VAT high group compared with the VAT low group (PZ0.005 and PZ0.008 respectively). Furthermore, FN buckling ratio was significantly higher in the VAT high group compared with the VAT low group (PZ0.02). Multivariate t-test on all the above-mentioned QCT-derived hip parameters across VAT groups revealed overall significant effects (PZ0.027). 
Figure 1
Correlations between BMI and SAT (A), WC and SAT (B), BMI and VAT (C), and WC and VAT (D). Open circle represents each trial subject (nZ72). r and P value from the Spearman's rank-order correlation.
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At LS, vBMD trab was non-significantly lower in the VAT high group compared with the VAT low group (PZ0.22). DXA-derived aBMD at FN was significantly lower in the VAT high group compared with the VAT low group (PZ0.03), while no difference could be detected at LS (PZ0.96).
HRpQCT-derived bone parameters across visceral fat median
HRpQCT-derived bone parameters revealed no significant differences between VAT groups in any structural parameters in peripheral bone (Table 2) .
Bone biochemistry across visceral fat median
Multivariate t-test on bone biochemistry across VAT groups failed to show overall significant effects (PZ0.60), thus markers of bone turnover, calcium metabolism, and sex hormone status did not differ between VAT groups. Table 3 presents the uncorrected P values.
Distribution of fat and sex hormones across E 2 median
In order to investigate the effect of E 2 on bone, the population was divided into two groups for comparison based on E 2 median (E 2 low and E 2 high ). Median E 2 for E 2 low and E 2 high were 20.0 and 70.5 pmol/l respectively (P!0.001). In addition, estrone was different between E 2 groups (Table 4 ). Testosterone and androstenedione, which are converted by aromatase to E 2 and estrone, respectively, and SHBG and insulin were comparable between groups (Table 4) . Clinical characteristics such as age, weight, BMI, and WC did not differ between groups, nor did measures of whole-body fat mass, VAT, and SAT (Table 4) .
Bone density and structural parameters across E 2 median
At the lumbar spine, vBMD trab was significantly lower in the E 2 low group compared with the E 2 high group (PZ0.04). Multivariate t-test on all QCT-derived hip parameters failed to show overall significant effects of E 2 at the hip (PZ0.25). The uncorrected P values are presented in Table 5 . DXA-derived aBMD at FN was significantly lower in the E 2 low group compared with the E 2 high group (PZ0.02), and a similar yet only borderline significant difference was found at LS (PZ0.058).
HRpQCT-derived bone parameters across E 2 median BV/TV and Tb.N were significantly lower and Tb.Sp significantly higher in the E 2 low group compared with the E 2 high group at both distal radius and distal tibia (Table 5 ).
Bone biochemistry across E 2 median
Multivariate t-test on bone biochemistry across E 2 groups failed to show overall significant effects (PZ0.16), thus markers of bone turnover and vitamin D levels did not differ between groups (Table 6 ).
Impact of testosterone on bone parameters
Thirty-six percent of the study population had testosterone deficiency with a testosterone level below 10.4 nmol/l (8.0G1.6 nmol/l). The remaining 64% of the population In addition, the structural parameters in peripheral bone were not significantly different between testosterone groups (data not shown).
Impact of lean body mass on bone parameters
Lean body mass below (lean low ) and above population mean (lean high ) did not affect lumbar spine vBMD trab or hip vBMD integral (neither TH nor site-specific). The structural parameters in radius were not significantly different between lean mass groups either. However, men with Lean high had significantly higher tibia BV/TV, Tb.N, and lower Tb.Sp (data not shown).
Relation between effects of VAT and E 2 at the hip
Multiple linear regression analysis revealed that VAT volume and E 2 levels were significantly and independently associated with THvBMD integral (VAT: standardized bZK0.316, PZ0.007 and E 2 : standardized bZ0.261, PZ0.029), whereas testosterone and lean body mass were not associated with THvBMD integral (testosterone: PZ0.87 and lean mass: PZ0.70). Results were unchanged when the metabolic markers (IL6, HDL, and ALT) were included in the regression analysis. Then, the population was grouped according to VAT volume and E 2 levels into four groups (E 2 low CVAT high (nZ16), E 2 low CVAT low (nZ20), E 2 high CVAT high (nZ20), and E 2 high CVAT low (nZ16)). Integral vBMD at TH differed between groups (ANOVA overall PZ0.011) and post hoc testing showed significantly lower TH vBMD integral in the E 2 low CVAT high group compared with the E 2 high CVAT low group (PZ0.006) ( Fig. 2A) . FN T-score was significantly lower in the E 2 low CVAT high group compared with the E 2 high CVAT low group (K1.04G0.78 vs K0.13G0.70, PZ0.004), and the prevalence of osteopenia was 50.0 and 6.3% respectively (Fig. 2B) .
Discussion
In this cross-sectional study of 72 middle-aged obese men with MetS, we found that men with VAT volume above population median had lower integral and trabecular vBMD at the hip, and lower Ct.Th and higher buckling ratio at FN, indicating a more fragile bone. E 2 levels seemed more important at lumbar spine and the peripheral bones, as men with E 2 below population median had lower lumbar spine vBMD trab , reduced BV/TV and Tb.N, and increased Tb.Sp at tibia and radius, while effects were less pronounced at the hip.
This population was very homogeneous and no correlations between VAT and BMI or WC were found. This allows us to interpret data without adjustments for BMI or WC that may confound results due to collinearity. Other studies have shown correlations between VAT and BMI or WC (40, 41) , which is probably due to inclusion of populations with a large variability in age and BMI. Participants in our study all had relatively high amounts of VAT regardless of their BMI and WC, which explains the lack of correlation. Dividing the study subjects in two groups based on population-median VAT yielded no differences in age, BMI, WC, or SAT between groups, confirming that the impaired bone-specific outcomes observed in the VAT high group are not biased by these characteristics. The use of QCT and HRpQCT provides measures of not only bone density, but also bone geometry and strength. The QCT technique reduces noise from excess soft tissue (42) , which is why QCTderived vBMD may predict bone strength better in this category of patients, compared with DXA (43, 44) . At the hip, QCT estimates integral bone density, trabecular bone density, and cortical bone density. The latter should be cautiously interpreted as cortex is very thin, and the resolution in scans with 3 mm slice thickness is suboptimal when discriminating cortical and trabecular compartments (45, 46) . We found lower integral and trabecular vBMD at all measured hip sites, and lower Ct.Th and higher buckling ratio at FN in the VAT high group. Furthermore, vBMD cortical was significantly higher in the VAT high group at TH and IT region. vBMD cortical primarily depends on cortical mineralization and porosity, without taking cortical area into account. However, bone size also determines resistance to load, and therefore CSA was measured at FN (34) . FN CSA total was comparable between groups, while the VAT high group had lower CSA cortical and Ct.Th, indicating that VAT promotes cortical thinning at the FN, primarily due to endocortical bone loss. This could be a result of excess endocortical remodeling leading to transition of cortical bone to trabecular bone and a change in edge detection when analyzing the QCT scans. We speculate that the endocortical zone was detected as trabecular bone compartment in the VAT high group, and would therefore expect the trabecular vBMD to be slightly overestimated. Indeed, we found a significantly lower trabecular bone density in the VAT high group. Thus, the true trabecular bone density may be even lower than our results indicate. We also investigated the effects of E 2 levels on bone. Dividing the study subjects based on populationmedian E 2 yielded no between-group differences in age, fat distribution, testosterone, androstenedione, or SHBG levels. This confirms that the impaired bone-specific outcomes we found in the E 2 low group are not biased by these characteristics. The E 2 low group was estrogen deficient with a median E 2 of 20 pmol/l and the E 2 high group was estrogen sufficient with a median E 2 of 71 pmol/l (reference range for men between 20 and 70 years: 48-170 pmol/l (http://www.ssi.dk/English.aspx assessed 4th July 2014)). Men in the E 2 low group had lower lumbar spine trabecular bone density and impaired geometric measures at tibia and radius. Khosla et al. have previously described that rate of bone loss at the radius was associated with total and bioavailable E 2 levels in elderly men but not in middle-aged men. Khosla et al. (47) also reported that bioavailable E 2 levels below 40 pmol/l were associated with significantly higher rates of bone loss and higher levels of bone resorption markers in elderly men than bioavailable E 2 levels above 40 pmol/l. Although steroid levels are difficult to compare between laboratories, there is a striking difference between total E 2 levels in our population and the population that Khosla et al. described. Median E 2 level in this study was 43 pmol/l vs 103 pmol/l (middle-aged men) and 110 pmol/l (elderly men) described by Khosla et al. This lower level of E 2 in our population could explain why we, in contrary to Khosla et al., found that E 2 is associated with bone density in middle-aged obese men. However, we did not find any differences in the bone resorption markers between groups, but the inter-individual variations in markers of bone resorption and bone formation are considerable.
The cross-sectional design may not be strong enough to demonstrate a possible difference. Surprisingly, fat distribution was unaffected by E 2 level. We would have expected to find a positive association between levels of E 2 and fat volume, due to increased aromatase activity (19, 20) . Maggio et al. (48) investigated men with and without MetS and found higher E 2 levels in men with MetS. Our population had low levels of testosterone and as testosterone is the substrate for adipose tissue aromatase to produce E 2 , low testosterone levels could explain why adipose tissue volume did not affect E 2 levels.
Multiple linear regression analysis revealed that VAT volume and E 2 levels were independently associated with THvBMD integral . Results presented in Fig. 2A clearly suggest an additive negative effect of VAT and low E 2 levels on bone in men. To ensure that these findings are relevant in a clinical perspective, we investigated the FN T-scores across groups. Interestingly, we found a clinically relevant difference of more than 1 in FN T-scores between the E 2 low CVAT high group compared with the E 2 high CVAT low group. Comparing osteopenia prevalence in the E 2 low C VAT high group (50.0%) with the E 2 high CVAT low group (6.3%), the clinical importance of VAT and E 2 levels certainly becomes evident. Nielson et al. (49) reported a prevalence of osteopenia of 11.9% in a population of Caucasian men aged between 45 and 74 years with a BMI of 30C. In comparison, our population comprises Caucasian men, average age 49 years (between 30 and 60 years) and average BMI 34 kg/m 2 . The prevalence of osteopenia in our population is higher (29.2%), which could be explained by the fact that all participants had MetS. Testosterone and lean body mass did not influence BMD at the spine or hip in our population. However, lean body mass positively affected structural parameters at the tibia. A recent study on 40 younger women and ten men with MetS has demonstrated that lean mass was positively associated with HRpQCT-derived bone parameters at both tibia and radius (50) . Unfortunately, they did not perform QCT at the hip or spine and did not have the opportunity to investigate effects of VAT and SAT separately.
Strengths of this study are the homogeneous population allowing us to interpret data without adjustments for BMI, WC, and testosterone levels, in addition to the use of several distinct methods to characterize bone. The limitations to this study are: first, the cross-sectional design does not allow us to determine causality. The differences we found in bone parameters across VAT and E 2 groups could be caused by an overall worse metabolic status. However, when including metabolic markers in a multiple linear regression analysis, VAT and E 2 are still the only markers significantly associated with THvBMD integral . Secondly, we included a limited number of subjects in this cohort. This study grounds on baseline data from another study (27) in which the sample size was determined. Post hoc power calculations suggested more than 90% power to detect a 10% difference between groups in TH vBMD integral . However, the risk of type II errors is relatively high in relation to the biochemical bone turnover markers, as the inter-individual variation is considerable. This may explain the lack of difference in bone turnover markers in this study.
In summary, we found that an increased amount of VAT in obese middle-aged men with MetS is associated with harmful effects on BMD, bone geometry, and bone strength at the hip, whereas the harmful effects of low estrogen levels primarily unfolds at the lumbar spine, radius, and tibia. In addition, we found that VAT volume and E 2 levels affect bone density at the hip independently and additively. The reduction in BMD in men with high VAT and low E 2 has a magnitude implying clinical importance for future fracture risk in men suffering from MetS.
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